Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 2,086 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Ulcerative Colitis
Interventions: Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more

Conditions: Non Cystic Fibrosis Bronchiectasis
Interventions: Ciprofloxacin dispersion for inhalation, Placebo; Drug
Lead sponsor: Aradigm Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 30
States / cities: Peoria, Arizona • Phoenix, Arizona • Downey, California + 27 more

Conditions: PNH
Interventions: Pegcetacoplan; Drug
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Interventions: AXS-05 (dextromethorphan-bupropion); Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 21
States / cities: Peoria, Arizona • Walnut Creek, California • Bonita Springs, Florida + 13 more

Conditions: Depressive Disorder, Major
Interventions: Venlafaxine ER, Dialogues Time to Talk Program; Drug · Behavioral
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 44
States / cities: Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 39 more

Conditions: Alzheimer Disease, Alzheimer Disease, Late Onset
Interventions: MemorEM 1000; Device
Lead sponsor: NeuroEM Therapeutics, Inc.; Industry
Eligibility: 63 Years to 84 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Ankylosing Spondylitis
Interventions: AIN457A; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 5 more

Conditions: Atopic Dermatitis
Interventions: APG777; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 23
States / cities: Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 20 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Inhaled Nitric Oxide; Drug
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: Not listed
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Atopic Dermatitis
Interventions: Abrocitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 11
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more

Conditions: Major Depressive Disorder
Interventions: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 140
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more

Conditions: Mild to Moderate Traumatic Brain Injury
Interventions: PoNS Treatment; Device
Lead sponsor: Helius Medical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Bipolar Disorder, Mania
Interventions: divalproex sodium extended release; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, Hereditary Angioedema - Type 3, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema Type III, Hereditary Angioedema (HAE), Hereditary Angioedema Type I and II, HAE With Normal C1 Esterase Inhibitor
Interventions: deucrictibant; Drug
Lead sponsor: Pharvaris Netherlands B.V.; Industry
Eligibility: 12 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 9 more

Conditions: Immune Thrombocytopenia
Interventions: Rilzabrutinib; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 8
States / cities: Peoria, Illinois • Bethesda, Maryland • Boston, Massachusetts + 4 more

Conditions: Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
Interventions: AK002; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 14 more

Conditions: Colorectal Carcinoma
Interventions: Metformin ER; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Migraine Disorders
Interventions: Botulinum Toxin Type A, Placebo (saline); Biological · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ulcerative Colitis
Interventions: Brazikumab Maintenance Dose, Brazikumab Induction Dose; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Chula Vista, California • Lancaster, California • Colorado Springs, Colorado + 7 more

Conditions: Hypertension, Pulmonary
Interventions: Ambrisentan; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 8 Years to 18 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Long QT Syndrome Type 3
Interventions: Eleclazine, Eleclazine placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Rochester, Minnesota • New York, New York • Rochester, New York

Conditions: Cushing's Disease
Interventions: Pasireotide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 10
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 6 more

Conditions: Major Depressive Disorder
Interventions: BHV-7000; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 66
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Edasalonexent; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 4 Years to 12 Years · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 15
States / cities: Sacramento, California • Atlanta, Georgia • Iowa City, Iowa + 11 more

Search by objective public record fields.

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

Pegcetacoplan Long Term Safety and Efficacy Extension Study

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program

Transcranial Electromagnetic Treatment Against Alzheimer's Disease

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

PoNS Clinical Experience Program (TBI)

Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

Open-label Extension Study of Brazikumab in Ulcerative Colitis

Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy